Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma [version 1; referees: 2 approved]

by Michael W. Bishop, Katherine A. Janeway
Published 2016-07-01

Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approa...

by Kevin Campbell, David Shulman, Katherine A. Janeway, Steven G. DuBois
Published 2018-01-01

Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children’s Onco...

by Michael D. Kinnaman, Chong Zhu, Daniel A. Weiser, Sana Mohiuddin, Pooja Hingorani, Michael Roth, Jonathan Gill, Katherine A. Janeway, Richard Gorlick, Stephen L. Lessnick, Patrick J. Grohar
Published 2020-01-01

Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST].

by Lorna Kelly, Kenneth Bryan, Su Young Kim, Katherine A Janeway, J Keith Killian, Hans-Ulrich Schildhaus, Markku Miettinen, Lee Helman, Paul S Meltzer, Matt van de Rijn, Maria Debiec-Rychter, Maureen O'Sullivan, NIH Pediatric and Wild-Type GIST Clinic
Published 2013-01-01

Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology

by David S. Shulman, Lulla V. Kiwinda, Stacey Edwards, Catherine M. Clinton, Sarah Hunt, Lianne Greenspan, Kristen D. Lawler, Gregory Reaman, Hasan Al‐Sayegh, Kira Bona, Allison F. O'Neill, Suzanne Shusterman, Katherine A. Janeway, Andrew E. Place, Susan N. Chi, Clement Ma, Steven G. DuBois
Published 2021-04-01

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

by Lisa M. Kopp, Richard B. Womer, Cindy L. Schwartz, David H. Ebb, Vivian I. Franco, David Hall, Donald A. Barkauskas, Mark D. Krailo, Holcombe E. Grier, Paul A. Meyers, Leonard H. Wexler, Neyssa M. Marina, Katherine A. Janeway, Richard Gorlick, Mark L. Bernstein, Steven E. Lipshultz, for the Children’s Oncology Group
Published 2019-10-01

A single‐institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors

by Raja Shaikh, Brent R. Weil, Christopher B. Weldon, Nan Chen, Wendy B. London, Morgan Krush, Megan Anderson, Mark Gebhardt, Alanna J. Church, Steven G. DuBois, Yana Pikman, Jennifer Spidle, Catherine B. Wall, Angela Feraco, Nicole J. Ullrich, Jennifer W. Mack, Elizabeth Mullen, Junne Kamihara, Suzanne Forrest, Suzanne Shusterman, Katherine A. Janeway, Ahmad Alomari, Horacio Padua, Carlos Rodriguez‐Galindo, Allison F. O'Neill
Published 2023-06-01

An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma

by David S. Shulman, Sarah B. Whittle, Didier Surdez, Kelly M. Bailey, Enrique de Álava, Jason T. Yustein, Adam Shlien, Masanori Hayashi, Alexander J. R. Bishop, Brian D. Crompton, Steven G. DuBois, Neerav Shukla, Patrick J. Leavey, Stephen L. Lessnick, Heinrich Kovar, Olivier Delattre, Thomas G. P. Grünewald, Cristina R. Antonescu, Ryan D. Roberts, Jeffrey A. Toretsky, Franck Tirode, Richard Gorlick, Katherine A. Janeway, Damon Reed, Elizabeth R. Lawlor, Patrick J. Grohar
Published 2022-09-01

Integrated genetic and pharmacologic interrogation of rare cancers

by Andrew L. Hong, Yuen-Yi Tseng, Glenn S. Cowley, Oliver Jonas, Jaime H. Cheah, Bryan D. Kynnap, Mihir B. Doshi, Coyin Oh, Stephanie C. Meyer, Alanna J. Church, Shubhroz Gill, Craig M. Bielski, Paula Keskula, Alma Imamovic, Sara Howell, Gregory V. Kryukov, Paul A. Clemons, Aviad Tsherniak, Francisca Vazquez, Brian D. Crompton, Alykhan F. Shamji, Carlos Rodriguez-Galindo, Katherine A. Janeway, Charles W. M. Roberts, Kimberly Stegmaier, Paul van Hummelen, Michael J. Cima, Robert S. Langer, Levi A. Garraway, Stuart L. Schreiber, David E. Root, William C. Hahn, Jesse S. Boehm
Published 2016-06-01

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

by Andrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, Won-Jun Kim, Bryan D Kynnap, Mihir B Doshi, Guillaume Kugener, Gabriel J Sandoval, Thomas P Howard, Ji Li, Xiaoping Yang, Michelle Tillgren, Mahmhoud Ghandi, Abeer Sayeed, Rebecca Deasy, Abigail Ward, Brian McSteen, Katherine M Labella, Paula Keskula, Adam Tracy, Cora Connor, Catherine M Clinton, Alanna J Church, Brian D Crompton, Katherine A Janeway, Barbara Van Hare, David Sandak, Ole Gjoerup, Pratiti Bandopadhayay, Paul A Clemons, Stuart L Schreiber, David E Root, Prafulla C Gokhale, Susan N Chi, Elizabeth A Mullen, Charles WM Roberts, Cigall Kadoch, Rameen Beroukhim, Keith L Ligon, Jesse S Boehm, William C Hahn
Published 2019-03-01